Two drugs used together for glioma that came back
Original title: A single-center retrospective study evaluating the efficacy of anlotinib plus temozolomide for recurrent glioma based on real-world data.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors only looked back at records of people already treated, not a real trial.
The short version
Doctors looked back at 39 people who took two drugs for a brain tumor that returned.
What was studied. Doctors at one hospital reviewed the records of 39 people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary came back. Each person took a pill called anlotinib along with the drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary.
What they found. Typical time before the tumor grew again was 7.57 months. Typical time people lived after starting the two drugs was 17.57 months. Side effects were mostly mild, and no one died from the treatment.
What this means, and what it doesn't
What it could mean: This pair of drugs may help some people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary comes back. Both drugs already exist, so it could be something to ask your doctor about.
What it doesn't mean: This was not a real trial. Doctors only looked back at old records at one hospital. No one was compared to people who got other care. So we cannot say the drugs caused these results. The authors say large trials are still needed. This is not a cure, and it is not settled care.
Source: PubMed, July 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.